Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer

BackgroundPucotenlimab, also called HX008, is a humanized anti-PD-1 antagonist IgG4 mAb. It blocks programmed cell death protein 1 (PD-1), programmed-death ligand 1 (PD-L1), and programmed death ligand-2 (PD-L2). In the CBCSG 006 trial, gemcitabine plus cisplatin (GP) has shown impressive antitumor...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Jun Cao, Biyun Wang, Jian Zhang, Zhonghua Tao, Leiping Wang, Xichun Hu
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2022-08-01
Serija:	Frontiers in Oncology
Teme:	immunotherapy pucotenlimab gemcitabine cisplatin metastatic triple-negative breast cancer
Online dostop:	https://www.frontiersin.org/articles/10.3389/fonc.2022.837963/full
Oznake:	Označite Brez oznak, prvi označite!